Bioline RX Ltd Sponsored ADR (BLRX) has released an update.
BioLineRx Ltd. has announced a poster presentation on their product, APHEXDA (motixafortide), which is used to improve apheresis center efficiency in multiple myeloma patients, at the ASFA 2024 Annual Meeting. The presentation will highlight the product’s ability to reduce the number of apheresis sessions needed for stem cell collection, based on data from the GENESIS Phase 3 trial. This research could impact clinical decisions, patient experience, and cost management in the treatment of multiple myeloma.
For further insights into BLRX stock, check out TipRanks’ Stock Analysis page.
